Deborah R. Kaye

Duke University

$579,044

Attributed

$579,044

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $144.8K · FY2022–25

$200K$150K$100K$50K$0

'22

'23

'24

'25

Funding mix

By agency

NIH$579,044 · 1

By mechanism

K08$579,044 · 1

Top collaborators

No co-investigators on record.

Most similar at Duke University

Same institution · by research overlap

Others in their field

Other Rising Stars on “Docetaxel”

Feng Yang · Baylor College Of Medicine$1,431,666
Ravi Amrit Madan · Massachusetts General Hospital$1,203,094
Aaron D Schuler · Syntrix Biosystems, Inc.$1,024,451
Daniel Louis Hertz · University Of Michigan At Ann Arbor$831,342
Meghna S Trivedi · University Of Michigan At Ann Arbor$831,342
Victor Zaporojan · Maia Biotechnology, Inc.$770,168

Research focus

DocetaxelEconomicsAffectAdherenceAcceptability And FeasibilityAdvanced Prostate CancerCancer CareCancer PatientAwardCareer DevelopmentAwarenessClinicClinical InfrastructureClinical Trials DesignCombined Modality TherapyComparative EffectivenessCostCost OutcomesDecision MakingCareerDesignDevelopment PlansCare ProvidersEnsure

Grant awards (4)

Improving outcomes of patients with advanced prostate cancer through a better understanding of provider decision-making$144,761

K08 · FY2025 · CA · contact PI

Improving outcomes of patients with advanced prostate cancer through a better understanding of provider decision-making$144,761

K08 · FY2024 · CA · contact PI

Improving outcomes of patients with advanced prostate cancer through a better understanding of provider decision-making$144,761

K08 · FY2023 · CA · contact PI

Improving outcomes of patients with advanced prostate cancer through a better understanding of provider decision-making$144,761

K08 · FY2022 · CA · contact PI